{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:31:33Z","timestamp":1769556693468,"version":"3.49.0"},"reference-count":41,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intrapleural perfusion hyperthermic chemotherapy (IPHC) can be used to select specific lung cancer cells of a certain genotype. Some genetic mutations, especially epidermal growth factor receptor (EGFR) mutations, are potential markers for EGFR or other targeted therapies. Here, we report a unique case of a patient with EGFR p.V774M\/p. S768I mutations that were associated with prolonged stable disease after treatment with IHPC, especially following furmonertinib\u2010based treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>A 47\u2010year\u2010old Chinese female patient was admitted to a regional cancer hospital and presented with malignant pleural effusion (MPE). The TNM and clinical stages were identified as T2aN2M1c and IVB, respectively. The TPS value is 40%. IHP combined with chemotherapy was then carried out to remove MPE. For first\u2010stage treatment, three cycles of afatinib\u2010based adjuvant chemotherapy beginning in September 2022 were given, and the degree of pleural effusion on the left side of the chest was not reduced. The best response (BOR) assessment of the local lesion was a partial response (PR). Furmonertinib\u2010based adjuvant monotherapy was performed from May 2023 to July 2024. The BOR evaluation results during the monotherapy courses were all judged as SD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The EGFR p.V774M\/p.The S768I mutation contributed to improving the efficiency of furmonertinib\u2010based therapy for NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cnr2.70444","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T04:51:42Z","timestamp":1767156702000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<scp>EGFR<\/scp>\n                    p.\n                    <scp>V774M<\/scp>\n                    \/p. the\n                    <scp>S768I<\/scp>\n                    Compound Mutation in\n                    <scp>NSCLC<\/scp>\n                    Is a Good Prognostic Marker for\n                    <scp>IPHC<\/scp>\n                    \u2010 and Furmonertinib\u2010Based Treatment: A Case Report"],"prefix":"10.1002","volume":"9","author":[{"given":"Yanan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy  Baoding Hebei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanying","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy  Baoding Hebei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4617-4561","authenticated-orcid":false,"given":"Zizheng","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy  Baoding Hebei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9047-8088","authenticated-orcid":false,"given":"Ling","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy  Baoding Hebei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy  Baoding Hebei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy  Baoding Hebei China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.IJC_52_21"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12505"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2950751"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-4975(94)00614-D"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2016.06.04"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13019-024-02751-6"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408440"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3302"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011110-130206"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01626"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02768-z"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.11.005"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-751"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071590"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.09.015"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1159308"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12539-013-0149-x"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000543453"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00825"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6491"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2021.100787"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101183"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00026-1"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v9.i27.8220"},{"issue":"3","key":"e_1_2_14_28_1","first-page":"113","article-title":"Successful Treatment of a Patient With Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, With Afatinib","volume":"45","author":"Kutsuzawa N.","year":"2020","journal-title":"Tokai Journal of Experimental and Clinical Medicine"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01696-9"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0777-1"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00168-0"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1126325"},{"key":"e_1_2_14_33_1","first-page":"67","article-title":"Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, \u201cUncommon\u2010G719X, S768I, L861Q\u201d) Among the Third\u2010Generation EGFR TKIs?","volume":"13","author":"Zhang S. S.","year":"2022","journal-title":"Lung Cancer"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.976731"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00839-w"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.09.005"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12980"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000308"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000504"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2019.02.050"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203448"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.surge.2020.11.002"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70444","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.70444","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:11:58Z","timestamp":1769508718000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/cnr2.70444"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70444","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"2025-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70444"}}